Clinical efficacy and safety of erlotinib combined with chemotherapy in the treatment of advanced pancreatic cancer: A meta-analysis

CONCLUSION: Compared with a single chemotherapeutic modality, erlotinib combined with gemcitabine can prolong progression-free survival in pancreatic cancer, but does not improve survival benefit or disease control rate, and can increase the risk of diarrhea and rash.PMID:38577077 | PMC:PMC10989324 | DOI:10.4240/wjgs.v16.i3.921
Source: Cancer Control - Category: Cancer & Oncology Authors: Source Type: research